Citation Impact
Citing Papers
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
2003 Standout
Progress and challenges towards targeted delivery of cancer therapeutics
2018 Standout
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
2011 Standout
Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: the causative role of improper dissolution of Cremophor EL.
1995
Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel
2001
Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications
2004 Standout
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity
2005
Multistage Nanoparticles for Improved Delivery into Tumor Tissue
2012 StandoutNobel
Natural products: A continuing source of novel drug leads
2013 Standout
A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel
2001 Standout
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
2013 Standout
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
1996 Standout
Microemulsion-based media as novel drug delivery systems
2000 Standout
Principles of nanoparticle design for overcoming biological barriers to drug delivery
2015 Standout
Oral Anticoagulant Therapy
2012 Standout
Pharmaceutical and Physical Properties of Paclitaxel (Taxol †) Complexes with Cyclodextrins ‡
1995
Drug development from marine natural products
2008 Standout
The resurgence of platinum-based cancer chemotherapy
2007 Standout
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review
2002
Cremophor EL
2001 Standout
Paclitaxel (Taxol)
1995 Standout
Block copolymer micelles: preparation, characterization and application in drug delivery
2005 Standout
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment
2014 Standout
Pharmaceutical Applications of Cyclodextrins. 1. Drug Solubilization and Stabilization
1996 Standout
The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics
1991
Adverse Drug Events Related to Dosage Forms and Delivery Systems
1996
Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer
2006
To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery
2010 Standout
Polymer conjugates as anticancer nanomedicines
2006 Standout
Targeting multidrug resistance in cancer
2006 Standout
Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol®) and carboplatin in non-small cell lung cancer patients
2000
Triglyceride-Based Microemulsion for Intravenous Administration of Sparingly Soluble Substances
1998
Alternative formulations of paclitaxel
1997
Cardiotoxicity of Chemotherapeutic Agents
2000
Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions
1997
Relationship between red meat allergy and sensitization to gelatin and galactose-α-1,3-galactose
2012
Strategies in the design of nanoparticles for therapeutic applications
2010 Standout
Complement Activation by Cremophor EL as a Possible Contributor to Hypersensitivity to Paclitaxel: an In Vitro Study
1998
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
2010 Standout
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
Pharmaceutical development of anticancer agents derived from marine sources
2000
Doxil® — The first FDA-approved nano-drug: Lessons learned
2012 Standout
Hypersensitivity reactions from taxol.
1990 Standout
Role of Formulation Vehicles in Taxane Pharmacology
2001
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
Novel Taxol Formulations: Preparation and Characterization of Taxol-Containing Liposomes
1994
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
2008 Standout
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
2016 Standout
Nanoparticle and targeted systems for cancer therapy
2004 Standout
Cardiac disturbances during the administration of taxol.
1991
Paclitaxel and its formulations
2002 Standout
Delivering nanomedicine to solid tumors
2010 Standout
The dawning era of polymer therapeutics
2003 Standout
Animal Models of Complement-Mediated Hypersensitivity Reactions to Liposomes and Other Lipid-Based Nanoparticles
2007
Cancer of the Ovary
2004 Standout
Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor model.
1993
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
2005 Standout
Pharmaceutical Development of (Investigational) Anticancer Agents for Parenteral Use-A Review
1996
Agents that Release Histamine from Mast Cells
1983
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
2001 Standout
Therapeutic Nanoparticles for Drug Delivery in Cancer
2008 Standout
Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition
2006 Standout
INCIDENCE AND SEVERITY OF ANAPHYLACTOID REACTIONS TO COLLOID VOLUME SUBSTITUTES
1977 Standout
Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.
1999
Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
2009
Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer
2005 Standout
Cyclodextrin Drug Carrier Systems
1998 Standout
Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy.
2003
Multistage nanoparticle delivery system for deep penetration into tumor tissue
2011 StandoutNobel
Multicenter Phase II Trial of ABI-007, an Albumin-Bound Paclitaxel, in Women With Metastatic Breast Cancer
2005
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
2015 Standout
Phase I trial of cremophor EL with bolus doxorubicin.
1998
A non- surfactant formulation for alfaxalone based on an amorphous cyclodextrin: Activity studies in rats and dogs
1990
The patch-clamp technique in the study of secretion
1989 StandoutNobel
Works of P. Dormann being referenced
HISTAMINE RELEASE IN HUMAN SUBJECTS BY MODIFIED GELATIN (HAEMACCEL) AND DEXTRAN: AN EXPLANATION FOR ANAPHYLACTOID REACTIONS OBSERVED UNDER CLINICAL CONDITIONS?
1976
Histamine release in dogs by Cremophor El® and its derivatives: Oxethylated oleic acid is the most effective constituent
1977